A multicenter, randomized, double-blind, placebo-controlled, phase 2, 12-week treatment study followed by a 12 week open label phase and a 12-week follow-up period to assess the efficacy and safety of avdoralimab (IPH5401) C5aR blocking antibody in adult patients with chronic spontaneous urticaria resistant to H1-antihistamine treatment.
Latest Information Update: 01 Apr 2022
At a glance
- Drugs Avdoralimab (Primary)
- Indications Urticaria
- Focus Therapeutic Use
- Acronyms CRUSE
- 01 Apr 2022 Status changed from recruiting to discontinued.
- 05 Jan 2021 New trial record